Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Go online to PeerView.com/YEF860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. In collaboration with HealthTree Foundation, this “Seminars
and Tumor Board” program makes new developments in multiple myeloma
(MM) care comprehensible by focusing on how the “myelennial” tool
kit can be leveraged for different patient populations and in
different treatment settings. Using a series of case-based
sessions, our expert panelists provide instruction on the use of
next-generation triplets and quadruplets, maintenance strategies,
and effective therapeutics in early relapse and
treatment-refractory disease. Link cutting-edge evidence in MM to
clinical decisions in your own practice—watch today! Upon
completion of this activity, participants should be better able to:
Cite current practice recommendations and clinical evidence
surrounding the efficacy of novel proteasome inhibitor and IMiD
options, novel antibody platforms, targeted agents, and cellular
therapy across MM treatment settings; Select personalized,
evidence-based regimens with novel components for the management of
patients with newly diagnosed MM according to baseline
comorbidities, functional status, and patient preferences, among
other factors; Select evidence-based treatment plans for
relapsed/refractory MM that integrate novel antibody, targeted, and
CAR-T options into patient care; and Manage the unique toxicities
associated with innovative therapeutics in patients with MM,
including cytopenias, infusion-related events, ocular toxicity, and
cytokine release syndrome.